JP2004532227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532227A5 JP2004532227A5 JP2002583418A JP2002583418A JP2004532227A5 JP 2004532227 A5 JP2004532227 A5 JP 2004532227A5 JP 2002583418 A JP2002583418 A JP 2002583418A JP 2002583418 A JP2002583418 A JP 2002583418A JP 2004532227 A5 JP2004532227 A5 JP 2004532227A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- dihydro
- pyridinyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000002148 esters Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 12
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 10
- 239000003937 drug carrier Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- -1 perfluoro Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 239000005711 Benzoic acid Substances 0.000 claims 6
- 235000010233 benzoic acid Nutrition 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- NCOCDZBFSLWJJR-PKTZIBPZSA-N 4-[(2r)-2-[[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=C(Cl)C=CC=3)CC1=CC=2C1=CC=C(C(O)=O)C=C1 NCOCDZBFSLWJJR-PKTZIBPZSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 125000006383 alkylpyridyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- GLHIAFUUFYHCIJ-RTWAWAEBSA-N (1r)-1-(6-aminopyridin-3-yl)-2-[[(2r)-6-[4-(2h-tetrazol-5-yl)phenyl]-3,4-dihydro-2h-chromen-2-yl]methylamino]ethanol Chemical compound C1=NC(N)=CC=C1[C@@H](O)CNC[C@@H]1OC2=CC=C(C=3C=CC(=CC=3)C=3NN=NN=3)C=C2CC1 GLHIAFUUFYHCIJ-RTWAWAEBSA-N 0.000 claims 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- XSESTUCLKNZCGJ-UHSQPCAPSA-N 1-(4-chloro-2-methylphenyl)-3-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]sulfonylurea Chemical compound CC1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)C=C1 XSESTUCLKNZCGJ-UHSQPCAPSA-N 0.000 claims 1
- FSUIRDZQAZKAMK-IAPPQJPRSA-N 1-(4-fluorophenyl)-3-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]sulfonylurea Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(F)C=C1 FSUIRDZQAZKAMK-IAPPQJPRSA-N 0.000 claims 1
- SVDQIHLVRZJJMJ-PXJZQJOASA-N 1-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]sulfonyl-3-(4-methylphenyl)urea Chemical compound C1=CC(C)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)C=C1 SVDQIHLVRZJJMJ-PXJZQJOASA-N 0.000 claims 1
- LLSWMDSPHVOGKD-IAPPQJPRSA-N 1-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]sulfonyl-3-phenylurea Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1=CC=CC=C1 LLSWMDSPHVOGKD-IAPPQJPRSA-N 0.000 claims 1
- YWMCHQQXZXIIPB-SJORKVTESA-N 1-[[(2r)-2-[[[(2r)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]methyl]-3,4-dihydro-2h-chromene-6-carbonyl]amino]cyclopropane-1-carboxylic acid Chemical compound C1=NC(N)=CC=C1[C@@H](O)CNC[C@@H]1OC2=CC=C(C(=O)NC3(CC3)C(O)=O)C=C2CC1 YWMCHQQXZXIIPB-SJORKVTESA-N 0.000 claims 1
- YEYWVLQJCBVXLW-IAPPQJPRSA-N 1-cyclohexyl-3-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]sulfonylurea Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 YEYWVLQJCBVXLW-IAPPQJPRSA-N 0.000 claims 1
- NEQHVHSNHJQCBF-VPUSJEBWSA-N 2-(4-chlorophenoxy)-4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=1)=CC=C(C(O)=O)C=1OC1=CC=C(Cl)C=C1 NEQHVHSNHJQCBF-VPUSJEBWSA-N 0.000 claims 1
- BXAZPLFDHGKKOL-PXJZQJOASA-N 2-(4-ethoxycarbonylphenoxy)-4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound C1=CC(C(=O)OCC)=CC=C1OC1=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=CC=C1C(O)=O BXAZPLFDHGKKOL-PXJZQJOASA-N 0.000 claims 1
- OQSUPHPIRVUPBF-VPUSJEBWSA-N 2-(4-fluorophenoxy)-4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=1)=CC=C(C(O)=O)C=1OC1=CC=C(F)C=C1 OQSUPHPIRVUPBF-VPUSJEBWSA-N 0.000 claims 1
- OQDHXELLTUCNHY-VGSWGCGISA-N 2-chloro-5-fluoro-4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C1=CC(Cl)=C(C(O)=O)C=C1F OQDHXELLTUCNHY-VGSWGCGISA-N 0.000 claims 1
- UPGQXSWXIJXLSK-NOZRDPDXSA-N 3-(cyclopropylmethoxy)-4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C1=CC=C(C(O)=O)C=C1OCC1CC1 UPGQXSWXIJXLSK-NOZRDPDXSA-N 0.000 claims 1
- AQRSGCAKTMHAGY-SDJMYADNSA-N 3-[(e)-hex-1-enyl]-4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]benzoic acid Chemical compound CCCC\C=C\C1=CC(C(O)=O)=CC=C1C1=CC=C(O[C@@H](CNC[C@H](O)C=2C=NC=CC=2)CC2)C2=C1 AQRSGCAKTMHAGY-SDJMYADNSA-N 0.000 claims 1
- HBGBOHHJDZDJGB-RPWUZVMVSA-N 3-[2-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]ethyl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2CCC1=CC=CC(C(O)=O)=C1 HBGBOHHJDZDJGB-RPWUZVMVSA-N 0.000 claims 1
- OWTKRFQGTFKXNQ-PKTZIBPZSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2,6-dimethylbenzoic acid Chemical compound CC1=C(C(O)=O)C(C)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 OWTKRFQGTFKXNQ-PKTZIBPZSA-N 0.000 claims 1
- ALJJBOKUOINEBD-VWNXMTODSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(2-methoxyethoxy)benzoic acid Chemical compound C1=C(C(O)=O)C(OCCOC)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 ALJJBOKUOINEBD-VWNXMTODSA-N 0.000 claims 1
- BZVVLCMMOOIDHV-NOZRDPDXSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(2-methylpropoxy)benzoic acid Chemical compound C1=C(C(O)=O)C(OCC(C)C)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 BZVVLCMMOOIDHV-NOZRDPDXSA-N 0.000 claims 1
- ZLBKXPBEZWIACX-RSXGOPAZSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(2-methylpropyl)benzoic acid Chemical compound C1=C(C(O)=O)C(CC(C)C)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 ZLBKXPBEZWIACX-RSXGOPAZSA-N 0.000 claims 1
- PXPVVHPMXVMBOP-DGPALRBDSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(2-phenylethyl)benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=1)=CC=C(C(O)=O)C=1CCC1=CC=CC=C1 PXPVVHPMXVMBOP-DGPALRBDSA-N 0.000 claims 1
- WWQOMERSUMBCRS-IAPPQJPRSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(4-methoxyphenoxy)benzoic acid Chemical compound C1=CC(OC)=CC=C1OC1=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=CC=C1C(O)=O WWQOMERSUMBCRS-IAPPQJPRSA-N 0.000 claims 1
- ZCNDKNHXAYNDQT-IAPPQJPRSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(4-methylphenoxy)benzoic acid Chemical compound C1=CC(C)=CC=C1OC1=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=CC=C1C(O)=O ZCNDKNHXAYNDQT-IAPPQJPRSA-N 0.000 claims 1
- QYSINFPZMCNIDU-UHSQPCAPSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(4-methylphenyl)benzoic acid Chemical compound C1=CC(C)=CC=C1C1=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=CC=C1C(O)=O QYSINFPZMCNIDU-UHSQPCAPSA-N 0.000 claims 1
- VHCFCXIWHWHQCV-NAKRPHOHSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-(4-methylsulfonylphenoxy)benzoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=CC=C1C(O)=O VHCFCXIWHWHQCV-NAKRPHOHSA-N 0.000 claims 1
- MOVHPVPONWXHIR-IRLDBZIGSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 MOVHPVPONWXHIR-IRLDBZIGSA-N 0.000 claims 1
- OAJXNPVLACUJPN-GGAORHGYSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-methylbenzoic acid Chemical compound C1=C(C(O)=O)C(C)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 OAJXNPVLACUJPN-GGAORHGYSA-N 0.000 claims 1
- PHQMOLCASOFUNR-VPUSJEBWSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-phenoxybenzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=1)=CC=C(C(O)=O)C=1OC1=CC=CC=C1 PHQMOLCASOFUNR-VPUSJEBWSA-N 0.000 claims 1
- VJMINWBZFFKARA-VWNXMTODSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-propan-2-yloxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC(C)C)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 VJMINWBZFFKARA-VWNXMTODSA-N 0.000 claims 1
- ZDGWNVNZRSOUOW-VWNXMTODSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-2-propoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OCCC)=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=C1 ZDGWNVNZRSOUOW-VWNXMTODSA-N 0.000 claims 1
- XYAOQLLLBPYHJY-NOZRDPDXSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-3-(2-methylpropoxy)benzoic acid Chemical compound CC(C)COC1=CC(C(O)=O)=CC=C1C1=CC=C(O[C@@H](CNC[C@H](O)C=2C=NC=CC=2)CC2)C2=C1 XYAOQLLLBPYHJY-NOZRDPDXSA-N 0.000 claims 1
- YTVROTUURLAKHG-IRLDBZIGSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C1=CC=C(O[C@@H](CNC[C@H](O)C=2C=NC=CC=2)CC2)C2=C1 YTVROTUURLAKHG-IRLDBZIGSA-N 0.000 claims 1
- YZJGAHHGBFDEFY-GGAORHGYSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1C1=CC=C(O[C@@H](CNC[C@H](O)C=2C=NC=CC=2)CC2)C2=C1 YZJGAHHGBFDEFY-GGAORHGYSA-N 0.000 claims 1
- IRZPRVADTGJBFQ-VWNXMTODSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-3-propoxybenzoic acid Chemical compound CCCOC1=CC(C(O)=O)=CC=C1C1=CC=C(O[C@@H](CNC[C@H](O)C=2C=NC=CC=2)CC2)C2=C1 IRZPRVADTGJBFQ-VWNXMTODSA-N 0.000 claims 1
- ASYYJYASZWFNSY-NAKRPHOHSA-N 4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]-n-(4-methoxyphenyl)sulfonylpyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC(=O)C1=CC(C=2C=C3CC[C@H](CNC[C@H](O)C=4C=NC=CC=4)OC3=CC=2)=CC=N1 ASYYJYASZWFNSY-NAKRPHOHSA-N 0.000 claims 1
- KLBCDERROIKSHM-RPWUZVMVSA-N 4-[2-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]ethyl]benzoic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2CCC1=CC=C(C(O)=O)C=C1 KLBCDERROIKSHM-RPWUZVMVSA-N 0.000 claims 1
- LRFBGWSTPPWWDW-RPBOFIJWSA-N 4-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]thiophene-2-carboxylic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=C1)=CC=C1C1=CSC(C(O)=O)=C1 LRFBGWSTPPWWDW-RPBOFIJWSA-N 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- HTSGECRKWVPTEB-RPWUZVMVSA-N 5-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]furan-2-carboxylic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=C1)=CC=C1C1=CC=C(C(O)=O)O1 HTSGECRKWVPTEB-RPWUZVMVSA-N 0.000 claims 1
- JSPZGQIBLFFWEM-RPWUZVMVSA-N 5-[4-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]phenyl]thiophene-2-carboxylic acid Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(C=C1)=CC=C1C1=CC=C(C(O)=O)S1 JSPZGQIBLFFWEM-RPWUZVMVSA-N 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- UEDWDOWDNMRVKB-SQHAQQRYSA-N n-[6-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]pyridin-3-yl]benzenesulfonamide Chemical compound C([C@@H](OC1=CC=2)CNC[C@H](O)C=3C=NC=CC=3)CC1=CC=2C(N=C1)=CC=C1NS(=O)(=O)C1=CC=CC=C1 UEDWDOWDNMRVKB-SQHAQQRYSA-N 0.000 claims 1
- NGCUTHMQSLSFJS-IRLDBZIGSA-N n-[6-[(2r)-2-[[[(2r)-2-hydroxy-2-pyridin-3-ylethyl]amino]methyl]-3,4-dihydro-2h-chromen-6-yl]pyridin-3-yl]methanesulfonamide Chemical compound N1=CC(NS(=O)(=O)C)=CC=C1C1=CC=C(O[C@@H](CNC[C@H](O)C=2C=NC=CC=2)CC2)C2=C1 NGCUTHMQSLSFJS-IRLDBZIGSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28571901P | 2001-04-23 | 2001-04-23 | |
| US32451801P | 2001-09-26 | 2001-09-26 | |
| PCT/US2002/012940 WO2002085891A1 (en) | 2001-04-23 | 2002-04-22 | 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532227A JP2004532227A (ja) | 2004-10-21 |
| JP2004532227A5 true JP2004532227A5 (https=) | 2005-12-22 |
Family
ID=26963345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002583418A Withdrawn JP2004532227A (ja) | 2001-04-23 | 2002-04-22 | ベータ−３アデノレセプタ作動薬として有用な２，６−置換クロマン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6660752B2 (https=) |
| EP (1) | EP1389202B1 (https=) |
| JP (1) | JP2004532227A (https=) |
| AR (1) | AR035858A1 (https=) |
| DE (1) | DE60201437T2 (https=) |
| DO (1) | DOP2002000385A (https=) |
| ES (1) | ES2230487T3 (https=) |
| PE (1) | PE20021073A1 (https=) |
| WO (1) | WO2002085891A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| CA2566196A1 (en) * | 2004-05-05 | 2005-11-10 | F. Hoffmann-La Roche Ag | Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both |
| BRPI0515835A (pt) * | 2004-12-21 | 2008-08-12 | Hoffmann La Roche | derivados de tetralina e de indano e seus usos |
| ES2306275T3 (es) * | 2004-12-21 | 2008-11-01 | F. Hoffmann-La Roche Ag | Derivados de cromano y sus usos como ligandos dde receptores 5-ht. |
| CA2591810A1 (en) | 2004-12-21 | 2006-06-29 | F.Hoffmann-La Roche Ag | Chroman derivatives and uses thereof in the treatment of cns disorders |
| SI1831159T1 (sl) * | 2004-12-21 | 2010-04-30 | Hoffmann La Roche | Derivati tetralina in indana ter njune uporabe |
| RU2388748C2 (ru) * | 2004-12-21 | 2010-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные тетралина и индана и их применения в качестве антагонистов 5-нт |
| JP2008530229A (ja) | 2005-02-17 | 2008-08-07 | ワイス | シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体 |
| CA2628173A1 (en) * | 2005-11-03 | 2007-05-10 | F. Hoffmann-La Roche Ag | Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
| GB0526252D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EP2418202B1 (en) | 2006-03-31 | 2014-01-29 | Novartis AG | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors |
| MX2008015511A (es) * | 2006-06-20 | 2008-12-18 | Hoffmann La Roche | Derivados de arilsulfonilnaftaleno y usos de los mismos. |
| AU2007263075A1 (en) * | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Arylsulfonamidyl tetralin derivatives and uses thereof |
| BRPI0713736A2 (pt) * | 2006-06-20 | 2014-11-18 | Hoffmann La Roche | Derivados de tetralina e indano e emprego destes |
| SI2750677T1 (sl) * | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| CA2895256C (en) | 2013-01-09 | 2021-06-01 | BASF Agro B.V. | Process for the preparation of substituted oxiranes and triazoles |
| WO2014207648A1 (en) * | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| CN106028817A (zh) | 2013-07-08 | 2016-10-12 | 巴斯夫农业公司 | 包含三唑化合物和生物农药的组合物 |
| EA037646B1 (ru) * | 2013-12-12 | 2021-04-27 | Басф Агро Б.В. | Способ получения замещенных триазолов |
| EA201892682A1 (ru) | 2014-06-25 | 2019-04-30 | Басф Агро Б.В. | Пестицидные композиции |
| US10053436B2 (en) | 2014-07-08 | 2018-08-21 | BASF Agro B.V. | Process for the preparation of substituted oxiranes and triazoles |
| AU2015289492B2 (en) | 2014-07-17 | 2020-02-20 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| UA120628C2 (uk) | 2014-11-07 | 2020-01-10 | Басф Се | Пестицидні суміші |
| DK3294720T3 (da) | 2015-05-08 | 2021-02-15 | Basf Agro Bv | Fremgangsmåde til fremstilling af terpinolenepoxid |
| EP3294700B1 (en) | 2015-05-08 | 2020-01-29 | BASF Agro B.V. | A process for the preparation of limonene-4-ol |
| US10370368B2 (en) | 2015-11-30 | 2019-08-06 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
| EP3383388B1 (en) | 2015-11-30 | 2021-04-14 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as blt1 antagonists |
| ES3056157T3 (en) | 2016-03-16 | 2026-02-18 | Basf Se | Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals |
| US11241012B2 (en) | 2016-03-16 | 2022-02-08 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean |
| CA3015456C (en) | 2016-03-16 | 2024-09-17 | Basf Se | USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT |
| US10640477B2 (en) | 2016-06-15 | 2020-05-05 | BASF Agro B.V. | Process for the epoxidation of a tetrasubstituted alkene |
| MX2018015764A (es) | 2016-06-15 | 2019-08-29 | Basf Agro Bv | Proceso para la epoxidacion de un alqueno tetrasustituido. |
| GB201803394D0 (en) * | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| US12545649B2 (en) | 2019-11-18 | 2026-02-10 | Vanderbilt University | WDR5-MYC inhibitors |
| WO2024040267A2 (en) * | 2022-08-19 | 2024-02-22 | Mitokinin, Inc. | Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706764A (en) | 1969-04-16 | 1972-12-19 | Yoshitomi Pharmaceutical | Phenethylaminomethyl-chromanones and- thiochromanones |
| US3803176A (en) | 1969-05-09 | 1974-04-09 | Novo Terapeutisk Labor As | Sulfonylurea derivatives |
| GB1499323A (en) | 1974-03-22 | 1978-02-01 | Fisons Ltd | 6-substituted chromones and chromanones |
| DE3275295D1 (en) | 1981-11-12 | 1987-03-05 | Fisons Plc | Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them |
| EP0091749A3 (en) | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| ZA844519B (en) | 1983-06-24 | 1985-02-27 | Hoffmann La Roche | Dihydrobenzopyran derivatives |
| US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
| DE3411992A1 (de) | 1984-03-31 | 1985-10-10 | Bayer Ag, 5090 Leverkusen | Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US4727877A (en) * | 1984-12-18 | 1988-03-01 | Medtronic, Inc. | Method and apparatus for low energy endocardial defibrillation |
| GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
| US5163427A (en) * | 1990-11-14 | 1992-11-17 | Medtronic, Inc. | Apparatus for delivering single and multiple cardioversion and defibrillation pulses |
| US5117824A (en) * | 1990-11-14 | 1992-06-02 | Medtronic, Inc. | Apparatus for monitoring electrical physiologic signals |
| US5129392A (en) * | 1990-12-20 | 1992-07-14 | Medtronic, Inc. | Apparatus for automatically inducing fibrillation |
| FR2695387B1 (fr) | 1992-09-09 | 1994-10-21 | Adir | Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| BR9406823A (pt) | 1993-06-14 | 1996-03-26 | Pfizer | Aminas secundárias e agentes anti-diabéticos e antiobesidade |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| US5541197A (en) | 1994-04-26 | 1996-07-30 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| US5516917A (en) | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
| JPH08198866A (ja) | 1995-01-20 | 1996-08-06 | Tokyo Tanabe Co Ltd | 新規２−アミノ−１−フェニルエタノール化合物 |
| US5674254A (en) * | 1995-05-22 | 1997-10-07 | Vitatron Medical, B.V. | Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture |
| US5663194A (en) | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| FR2746395B1 (fr) * | 1996-03-22 | 1998-04-17 | Adir | Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP3708624B2 (ja) | 1996-03-27 | 2005-10-19 | キッセイ薬品工業株式会社 | ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体 |
| EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| ID22273A (id) | 1997-01-28 | 1999-09-23 | Merck & Co Inc | TIAZOL BENZENASULFONAMIDA SEBAGAI AGONIS β UNTUK PENGOBATAN DIABETES DAN OBESITAS |
| US5741312A (en) * | 1997-03-12 | 1998-04-21 | Vitatron Medical, B.V. | Pacemaker system and method with improved capture detection and threshold search |
| JP2001526282A (ja) * | 1997-12-19 | 2001-12-18 | バイエル・コーポレーシヨン | β−３アドレナリン受容体作用薬として有用なカルボキシル置換クロマン誘導体 |
| US6051586A (en) | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| US6469031B1 (en) * | 1998-12-18 | 2002-10-22 | Bayer Corporation | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| US6052621A (en) * | 1998-01-27 | 2000-04-18 | Vitatron Medical B.V. | System and method for inducing tachycardia |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| US6393316B1 (en) * | 1999-05-12 | 2002-05-21 | Medtronic, Inc. | Method and apparatus for detection and treatment of cardiac arrhythmias |
| US6647292B1 (en) * | 2000-09-18 | 2003-11-11 | Cameron Health | Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer |
| US6675042B2 (en) * | 2002-04-15 | 2004-01-06 | Charles D. Swerdlow | Defibrillation shock strength determination technology |
-
2002
- 2002-04-17 AR ARP020101393A patent/AR035858A1/es not_active Application Discontinuation
- 2002-04-22 JP JP2002583418A patent/JP2004532227A/ja not_active Withdrawn
- 2002-04-22 US US10/131,448 patent/US6660752B2/en not_active Expired - Fee Related
- 2002-04-22 DO DO2002000385A patent/DOP2002000385A/es unknown
- 2002-04-22 ES ES02723958T patent/ES2230487T3/es not_active Expired - Lifetime
- 2002-04-22 WO PCT/US2002/012940 patent/WO2002085891A1/en not_active Ceased
- 2002-04-22 DE DE60201437T patent/DE60201437T2/de not_active Expired - Fee Related
- 2002-04-22 EP EP02723958A patent/EP1389202B1/en not_active Expired - Lifetime
- 2002-04-23 PE PE2002000337A patent/PE20021073A1/es not_active Application Discontinuation
-
2003
- 2003-09-17 US US10/666,903 patent/US6919371B2/en not_active Expired - Fee Related
-
2005
- 2005-04-28 US US11/117,759 patent/US20050215594A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532227A5 (https=) | ||
| RU2454405C2 (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| JP4629978B2 (ja) | サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物 | |
| RU2429226C2 (ru) | Ингибиторы пролилгидроксилазы и способы их применения | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| US8669254B2 (en) | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | |
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| RU2012134093A (ru) | 4-фенокси-никотинамиды или 4-фенокси-пиримидин-5-карбоксамиды | |
| JP2007519754A5 (https=) | ||
| RU2011120969A (ru) | Новые фениламидные или пиридиламидные производные и их применение в качестве агонистов gpbari | |
| RU2017126199A (ru) | Биарильное производное в качестве агониста gpr120 | |
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2013517283A5 (https=) | ||
| RU2014147191A (ru) | Амидопроизводные как блокаторы ttx-s | |
| RU2016102313A (ru) | Биарильные производные в качестве агонистов gpr120 | |
| JP2008516902A5 (https=) | ||
| US20060276515A1 (en) | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | |
| RU2540069C2 (ru) | N-пиридин-3-ил или n-пиразин-2-ил карбоксамиды в качестве агентов, повышающих уровень холестерина лпвп | |
| CA2396965A1 (en) | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases | |
| JP2022510700A5 (https=) | ||
| JP5815874B2 (ja) | Ｈｄｌコレステロール上昇剤としての３−ピリジンカルボン酸ヒドラジド | |
| CA2628963A1 (en) | Benzene derivative or salt thereof | |
| HK1181759B (en) | N-pyridin-3-yl or n-pyrazin-2-yl carboxamides | |
| HK1193597A (en) | 3-pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents |